Aarti Drugs Limited (AARTIDRUGS.BO)
INR 330.65
(2.85%)
INR 330.65
(2.85%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 8.31 Billion INR | -15.77% |
| 2022 | 8.27 Billion INR | 64.25% |
| 2021 | 5.03 Billion INR | -16.07% |
| 2020 | 6 Billion INR | 48.49% |
| 2019 | 4.04 Billion INR | 28.88% |
| 2018 | 3.13 Billion INR | 5.0% |
| 2017 | 2.98 Billion INR | 3.18% |
| 2016 | 2.89 Billion INR | 14.94% |
| 2015 | 2.51 Billion INR | 5.33% |
| 2014 | 2.39 Billion INR | 11.46% |
| 2013 | 2.14 Billion INR | 20.87% |
| 2012 | 1.77 Billion INR | 41.25% |
| 2011 | 1.25 Billion INR | 33.88% |
| 2010 | 938.68 Million INR | -10.81% |
| 2009 | 1.05 Billion INR | 25.18% |
| 2008 | 840.68 Million INR | 38.58% |
| 2007 | 606.63 Million INR | 5.5% |
| 2006 | 574.99 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2.04 Billion INR | 5.36% |
| 2024 Q1 | 1.55 Billion INR | -15.12% |
| 2023 Q4 | 1.83 Billion INR | -8.6% |
| 2023 Q2 | 2.12 Billion INR | -1.05% |
| 2023 FY | 6.97 Billion INR | -15.77% |
| 2023 Q1 | 2.14 Billion INR | -5.35% |
| 2023 Q3 | 2 Billion INR | -5.56% |
| 2022 FY | 8.27 Billion INR | 64.25% |
| 2022 Q4 | 2.26 Billion INR | 12.85% |
| 2022 Q2 | 2.06 Billion INR | 7.03% |
| 2022 Q1 | 1.93 Billion INR | 343.27% |
| 2022 Q3 | 2.01 Billion INR | -2.68% |
| 2021 FY | 5.03 Billion INR | -16.07% |
| 2021 Q4 | -793.44 Million INR | -136.84% |
| 2021 Q3 | 2.15 Billion INR | 16.97% |
| 2021 Q1 | 1.83 Billion INR | 458.25% |
| 2021 Q2 | 1.84 Billion INR | 0.24% |
| 2020 Q4 | -512.7 Million INR | -124.83% |
| 2020 Q1 | 2.25 Billion INR | 499.14% |
| 2020 Q2 | 2.19 Billion INR | -2.31% |
| 2020 Q3 | 2.06 Billion INR | -6.12% |
| 2020 FY | 6 Billion INR | 48.49% |
| 2019 Q3 | 1.63 Billion INR | 1.37% |
| 2019 Q4 | -564.06 Million INR | -134.55% |
| 2019 FY | 4.04 Billion INR | 28.88% |
| 2019 Q2 | 1.61 Billion INR | 18.18% |
| 2019 Q1 | 1.36 Billion INR | 374.51% |
| 2018 FY | 3.13 Billion INR | 5.0% |
| 2018 Q3 | 1.27 Billion INR | 10.09% |
| 2018 Q1 | 1.2 Billion INR | -3.01% |
| 2018 Q4 | -496.51 Million INR | -138.99% |
| 2018 Q2 | 1.15 Billion INR | -3.89% |
| 2017 FY | 2.98 Billion INR | 3.18% |
| 2017 Q4 | 1.24 Billion INR | 0.94% |
| 2017 Q3 | 1.22 Billion INR | 4.24% |
| 2017 Q2 | 1.17 Billion INR | 22.77% |
| 2017 Q1 | 960.5 Million INR | -10.25% |
| 2016 Q1 | 1 Billion INR | 3.19% |
| 2016 Q4 | 1.07 Billion INR | 7.83% |
| 2016 FY | 2.89 Billion INR | 14.94% |
| 2016 Q2 | 1.08 Billion INR | 8.14% |
| 2016 Q3 | 992.5 Million INR | -8.36% |
| 2015 Q2 | 898.6 Million INR | 1.41% |
| 2015 Q4 | 970.6 Million INR | 7.55% |
| 2015 Q3 | 902.5 Million INR | 0.43% |
| 2015 Q1 | 886.1 Million INR | 679.25% |
| 2015 FY | 2.51 Billion INR | 5.33% |
| 2014 Q2 | 865.6 Million INR | 6.76% |
| 2014 Q4 | -152.97 Million INR | -117.62% |
| 2014 FY | 2.39 Billion INR | 11.46% |
| 2014 Q3 | 868.2 Million INR | 0.3% |
| 2014 Q1 | 810.8 Million INR | 991.5% |
| 2013 Q2 | 764.4 Million INR | 11.46% |
| 2013 Q3 | 785.8 Million INR | 2.8% |
| 2013 Q4 | -90.94 Million INR | -111.57% |
| 2013 FY | 2.14 Billion INR | 20.87% |
| 2013 Q1 | 685.8 Million INR | 457.17% |
| 2012 FY | 1.77 Billion INR | 41.25% |
| 2012 Q1 | 603.2 Million INR | 0.0% |
| 2012 Q2 | 680.9 Million INR | 12.88% |
| 2012 Q3 | 684.4 Million INR | 0.51% |
| 2012 Q4 | -192 Million INR | -128.05% |
| 2011 FY | 1.25 Billion INR | 33.88% |
| 2010 FY | 938.68 Million INR | -10.81% |
| 2009 FY | 1.05 Billion INR | 25.18% |
| 2008 FY | 840.68 Million INR | 38.58% |
| 2007 FY | 606.63 Million INR | 5.5% |
| 2006 FY | 574.99 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 68.947% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 94.624% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 33.112% |
| Granules India Limited | 16.79 Billion INR | 50.497% |
| Indoco Remedies Limited | 6.04 Billion INR | -37.655% |
| Achyut Healthcare Limited | 4.86 Million INR | -170980.045% |
| Ajanta Pharma Limited | 21.06 Billion INR | 60.519% |
| Alkem Laboratories Limited | 52.29 Billion INR | 84.098% |
| Alpa Laboratories Limited | 188.89 Million INR | -4302.552% |
| Brooks Laboratories Limited | 65.62 Million INR | -12573.272% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | -33.643% |
| Bajaj HealthCare Limited | 1.47 Billion INR | -465.034% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | -125.04% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 94.917% |
| Eris Lifesciences Limited | 10.42 Billion INR | 20.242% |
| FDC Limited | 8.33 Billion INR | 0.222% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 88.007% |
| Gufic Biosciences Limited | 4.16 Billion INR | -99.539% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | -34.254% |
| Ipca Laboratories Limited | 29.8 Billion INR | 72.103% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -1174.338% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -4215.016% |
| Lasa Supergenerics Limited | 121.02 Million INR | -6771.19% |
| Laurus Labs Limited | 24.62 Billion INR | 66.222% |
| Lupin Limited | 123.71 Billion INR | 93.278% |
| Mankind Pharma Limited | 44.52 Billion INR | 81.321% |
| Medicamen Biotech Limited | 495.49 Million INR | -1578.362% |
| Medico Remedies Limited | 262.14 Million INR | -3072.379% |
| Megasoft Limited | 342.07 Million INR | -2331.133% |
| NATCO Pharma Limited | 25.73 Billion INR | 67.687% |
| Piramal Pharma Limited | 24.47 Billion INR | 66.016% |
| RPG Life Sciences Limited | 2.48 Billion INR | -234.926% |
| Sigachi Industries Limited | 2 Billion INR | -315.336% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 96.783% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | -101.689% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -782.45% |
| Unichem Laboratories Limited | 4.86 Billion INR | -70.942% |
| Wanbury Limited | 1.73 Billion INR | -380.527% |
| Windlas Biotech Limited | 1.33 Billion INR | -521.168% |
| ZIM Laboratories Limited | 1.26 Billion INR | -556.428% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 93.358% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 1480.498% |
| Divi's Laboratories Limited | 32.44 Billion INR | 74.364% |
| Hester Biosciences Limited | 1.27 Billion INR | -552.942% |
| Procter & Gamble Health Limited | 5.78 Billion INR | -43.844% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | -434.278% |
| Bal Pharma Limited | 770.19 Million INR | -979.753% |
| Strides Pharma Science Limited | 14.38 Billion INR | 42.201% |
| Venus Remedies Limited | 2.18 Billion INR | -281.025% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | -42.612% |
| Nectar Lifesciences Limited | 2.97 Billion INR | -179.813% |
| Shilpa Medicare Limited | 3.54 Billion INR | -134.467% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | -81.545% |
| Suven Life Sciences Limited | -200.79 Million INR | 4241.596% |
| Ind-Swift Limited | 2.17 Billion INR | -282.789% |
| Valiant Laboratories Limited | -60.66 Million INR | 13808.626% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 63.365% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | -865.653% |
| Themis Medicare Limited | 1.5 Billion INR | -452.974% |
| Hikal Limited | 3.14 Billion INR | -164.588% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 82.214% |
| Sequent Scientific Limited | 2.97 Billion INR | -179.186% |
| Novartis India Limited | 1.32 Billion INR | -526.739% |
| Wockhardt Limited | 16.24 Billion INR | 48.792% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 57.663% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -56939.589% |
| Neuland Laboratories Limited | 8.24 Billion INR | -0.829% |
| Morepen Laboratories Limited | 6.16 Billion INR | -34.975% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -1240.292% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -1081.942% |